Elisabeth F. P. Peterse

Elisabeth F. P. Peterse

Auto-generated profile, based on publicly available information

Elisabeth F. P. Peterse

Department of Public Health, Erasmus MC, University Medical Center, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2018 in Cancer
Verified
Journal Article
Open access
PDF file
EPElisabeth F. P. Peterse
Elisabeth F. P. Peterse
RMReinier G. S. Meester
Reinier G. S. Meester
RSRebecca L. Siegel
Rebecca L. Siegel
JCJennifer C. Chen
Jennifer C. Chen
ADAndrea Dwyer
Andrea Dwyer
ILIris Lansdorp‐Vogelaar
Iris Lansdorp‐Vogelaar
BACKGROUND: In 2016, the Microsimulation Screening Analysis‐Colon (MISCAN‐Colon) model was used to inform the US Preventive Services Task Force colorectal cancer (CRC) screening guidelines. In this study, 1 of 2 microsimulation analyses to inform the update of the American Cancer Society CRC screening guideline, the authors re‐evaluated the optimal screening strategies in light of the increase in CRC diagnosed in young adults.METHODS: The authors adjusted the MISCAN‐Colon model to reflect the higher CRC incidence in young adults, who were assumed to carry forward escalated disease risk as they age. Life‐years gained (LYG; benefit), the number of colonoscopies (COL; burden) and the ratios of incremental burden to benefit (efficiency ratio [ER] = ΔCOL/ΔLYG) were projected for different screening strategies. Strategies differed with respect to test modality, ages to start (40 years, 45 years, and 50 years) and ages to stop (75 years, 80 years, and 85 years) screening, and screening intervals (depending on screening modality). The authors then determined the model‐recommended strategies in a similar way as was done for the US Preventive Services Task Force, using ER thresholds in accordance with the previously accepted ER of 39.RESULTS: Because of the higher CRC incidence, model‐predicted LYG from screening increased compared with the previous analyses. Consequently, the balance of burden to benefit of screening improved and now 10‐yearly colonoscopy screening starting at age 45 years resulted in an ER of 32. Other recommended strategies included fecal immunochemical testing annually, flexible sigmoidoscopy screening every 5 years, and computed tomographic colonography every 5 years.CONCLUSIONS: This decision‐analysis suggests that in light of the increase in CRC incidence among young adults, screening may be offered earlier than has previously been recommended. Cancer 2018;124:2964‐73. © 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.

1 April 2020 in Gastroenterology
Verified
Journal Article
Closed access
AAAlexi N. Archambault
Alexi N. Archambault
YSYu-Ru Su
Yu-Ru Su
JJJihyoun Jeon
Jihyoun Jeon
MTMinta Thomas
Minta Thomas
YLYi Lin
Yi Lin
RHRichard B. Hayes
Richard B. Hayes

6 August 2020 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
EPElisabeth F P Peterse
Elisabeth F P Peterse
RMReinier G S Meester
Reinier G S Meester
LJLucie de Jonge
Lucie de Jonge
AOAmir-Houshang Omidvari
Amir-Houshang Omidvari
FAFernando Alarid-Escudero
Fernando Alarid-Escudero
ILIris Lansdorp-Vogelaar
Iris Lansdorp-Vogelaar
Colorectal cancer (CRC) screening with colonoscopy and the fecal immunochemical test (FIT) is underused. Innovative tests could increase screening acceptance. This study determined which of the available alternatives is most promising from a cost-effectiveness perspective. The previously validated Microsimulation Screening Analysis-Colon model was used to evaluate the cost-effectiveness of screening with capsule endoscopy every 5 or 10 years, computed tomographic colonography every 5 years, the multi-target stool DNA test every 1 or 3 years, and the methylated SEPT9 DNA plasma assay (mSEPT9) every 1 or 2 years. We also compared these strategies with annual FIT screening and colonoscopy screening every 10 years. Quality-adjusted life-years gained (QALYG), number of colonoscopies, and incremental cost-effectiveness ratios were projected. We assumed a willingness-to-pay threshold of $100 000 per QALYG. Among the alternative tests, computed tomographic colonography every 5 years, annual mSEPT9, and annual multi-target stool DNA screening had incremental cost-effectiveness ratios of $1092, $63 253, and $214 974 per QALYG, respectively. Other screening strategies were more costly and less effective than (a combination of) these 3. Under the assumption of perfect adherence, annual mSEPT9 screening resulted in more QALYG, CRC cases averted, and CRC deaths averted than annual FIT screening but led to a high rate of colonoscopy referral (51% after 3 years, 69% after 5 years). The alternative tests were not cost-effective compared with FIT and colonoscopy. This study suggests that for individuals not willing to participate in FIT or colonoscopy screening, mSEPT9 is the test of choice if the high colonoscopy referral rate is acceptable to them.

30 May 2018 in Cancer
Verified
Journal Article
Open access
PDF file
RMReinier G. S. Meester
Reinier G. S. Meester
EPElisabeth F. P. Peterse
Elisabeth F. P. Peterse
AKAmy B. Knudsen
Amy B. Knudsen
AWAnne C. de Weerdt
Anne C. de Weerdt
JCJennifer C. Chen
Jennifer C. Chen
ILIris Lansdorp‐Vogelaar
Iris Lansdorp‐Vogelaar
BACKGROUND: Colorectal cancer (CRC) risk varies by race and sex. This study, 1 of 2 microsimulation analyses to inform the 2018 American Cancer Society CRC screening guideline, explored the influence of race and sex on optimal CRC screening strategies.METHODS: Two Cancer Intervention and Surveillance Modeling Network microsimulation models, informed by US incidence data, were used to evaluate a variety of screening methods, ages to start and stop, and intervals for 4 demographic subgroups (black and white males and females) under 2 scenarios for the projected lifetime CRC risk for 40‐year‐olds: 1) assuming that risk had remained stable since the early screening era and 2) assuming that risk had increased proportionally to observed incidence trends under the age of 40 years. Model‐based screening recommendations were based on the predicted level of benefit (life‐years gained) and burden (required number of colonoscopies), the incremental burden‐to‐benefit ratio, and the relative efficiency in comparison with strategies with similar burdens.RESULTS: When lifetime CRC risk was assumed to be stable over time, the models differed in the recommended age to start screening for whites (45 vs 50 years) but consistently recommended screening from the age of 45 years for blacks. When CRC risk was assumed to be increased, the models recommended starting at the age of 45 years, regardless of race and sex. Strategies recommended under both scenarios included colonoscopy every 10 or 15 years, annual fecal immunochemical testing, and computed tomographic colonography every 5 years through the age of 75 years.CONCLUSIONS: Microsimulation modeling suggests that CRC screening should be considered from the age of 45 years for blacks and for whites if the lifetime risk has increased proportionally to the incidence for younger adults. Cancer 2018;124:2974‐85. © 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.

13 January 2022 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
AAAlexi N Archambault
Alexi N Archambault
JJJihyoun Jeon
Jihyoun Jeon
YLYi Lin
Yi Lin
MTMinta Thomas
Minta Thomas
THTabitha A Harrison
Tabitha A Harrison
RHRichard B Hayes
Richard B Hayes
The incidence of colorectal cancer (CRC) among individuals aged younger than 50 years has been increasing. As screening guidelines lower the recommended age of screening initiation, concerns including the burden on screening capacity and costs have been recognized, suggesting that an individualized approach may be warranted. We developed risk prediction models for early-onset CRC that incorporate an environmental risk score (ERS), including 16 lifestyle and environmental factors, and a polygenic risk score (PRS) of 141 variants. Relying on risk score weights for ERS and PRS derived from studies of CRC at all ages, we evaluated risks for early-onset CRC in 3486 cases and 3890 controls aged younger than 50 years. Relative and absolute risks for early-onset CRC were assessed according to values of the ERS and PRS. The discriminatory performance of these scores was estimated using the covariate-adjusted area under the receiver operating characteristic curve. Increasing values of ERS and PRS were associated with increasing relative risks for early-onset CRC (odds ratio per SD of ERS = 1.14, 95% confidence interval [CI] = 1.08 to 1.20; odds ratio per SD of PRS = 1.59, 95% CI = 1.51 to 1.68), both contributing to case-control discrimination (area under the curve = 0.631, 95% CI = 0.615 to 0.647). Based on absolute risks, we can expect 26 excess cases per 10 000 men and 21 per 10 000 women among those scoring at the 90th percentile for both risk scores. Personal risk scores have the potential to identify individuals at differential relative and absolute risk for early-onset CRC. Improved discrimination may aid in targeted CRC screening of younger, high-risk individuals, potentially improving outcomes.

1 December 2017 in Health Affairs
Verified
Journal Article
Closed access
EPElisabeth F. P. Peterse
Elisabeth F. P. Peterse
RMReinier G. S. Meester
Reinier G. S. Meester
AGAndrea Gini
Andrea Gini
CDChyke A. Doubeni
Chyke A. Doubeni
DADaniel S. Anderson
Daniel S. Anderson
ILIris Lansdorp-Vogelaar
Iris Lansdorp-Vogelaar
Financial barriers to colorectal cancer screening persist despite the Affordable Care Act (ACA). Medicare beneficiaries may face 20 percent coinsurance for a screening colonoscopy when the procedure includes the removal of polyps or follows a positive fecal screening test. Using an established microsimulation model, we estimated that waiving this coinsurance would result in 1.7 fewer colorectal cancer deaths (a decrease of 13 percent) and $17,000 higher colorectal cancer–related costs (an increase of 0.6 percent) for the Centers for Medicare and Medicaid Services per 1,000 sixty-five-year-olds, assuming a 10-percentage-point increase in the rates of first colonoscopy screening, follow-up, and surveillance. If the rates did not change, waiving coinsurance would increase total costs by $51,000 (1.9 percent) per 1,000 sixty-five-year-olds. Estimated screening benefits were comparable when fecal testing was assumed to be the primary screening method. Moreover, waiving coinsurance would be cost-effective if th...